预约演示

更新于：2025-05-07

Aranidipine

阿雷地平

更新于：2025-05-07

概要

基本信息

药物类型

小分子化药

别名

Aranidipine (JAN/INN)、Bec

+ [2]

靶点

Cav2.1

作用方式

抑制剂

作用机制

Cav2.1抑制剂(calcium voltage-gated channel subunit alpha1 A inhibitors)

治疗领域

神经系统疾病心血管疾病其他疾病

在研适应症

心绞痛高血压

非在研适应症-

原研机构-

在研机构-

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

(1996-01-01),

高血压

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C19H20N2O7

InChIKeyNCUCGYYHUFIYNU-UHFFFAOYSA-N

CAS号86780-90-7

关联

100 项与阿雷地平相关的临床结果

登录后查看更多信息

100 项与阿雷地平相关的转化医学

登录后查看更多信息

100 项与阿雷地平相关的专利（医药）

登录后查看更多信息

327

项与阿雷地平相关的文献（医药）

2025-05-04·Journal of Asthma

A decision tree analysis to evaluate the optimal approach to screen allergic bronchopulmonary aspergillosis in asthmatic patients

Article

作者: Rudramurthy, Shivaprakash Mandya ; Prasad, Kuruswamy Thurai ; Agarwal, Ritesh ; Sehgal, Inderpaul Singh ; Chakrabarti, Arunaloke ; Dhooria, Sahajal ; Soundappan, Kathirvel ; Aggarwal, Ashutosh Nath ; Garg, Mandeep ; Muthu, Valliappan ; Saxena, Puneet

BACKGROUNDVarious methods are available to screen for allergic bronchopulmonary aspergillosis (ABPA) in asthma, but their comparative performance remains uncertain.OBJECTIVESTo identify the optimal screening algorithm for ABPA in asthmatic patients and evaluate the crude cost of various diagnostic approaches.METHODSWe performed a post hoc analysis of prospectively collected data from consecutive adult asthmatic patients evaluated for ABPA. The diagnosis was based on the revised International Society for Human and Animal Mycology ABPA Working Group criteria. Initial evaluations included measurements of serum Aspergillus fumigatus-IgE (≥0.35 kUA/L), serum total IgE (≥500 IU/mL), serum A. fumigatus-IgG (≥27 mgA/L), blood eosinophil count (BEC ≥500 cells/μL), and chest CT findings. A decision tree was manually constructed using recursive partitioning to identify the most effective diagnostic pathway.RESULTSAmong 543 adult asthmatics, 106 were diagnosed with ABPA. Serum A. fumigatus-IgE was positive in 221 (40.7%) patients, while serum total IgE was elevated (≥500 IU/mL) in 300 (55.3%) patients. The serum total IgE-based approach required 196 additional tests during screening, compared to 115 in the A. fumigatus-IgE method. The BEC-based strategy missed 28 cases of ABPA. Although the CT-directed protocol had the fewest false positives, it required 437 additional screening radiographic procedures and missed eight ABPA cases. The A. fumigatus-IgE pathway emerged as the most cost-effective, whereas imaging-based strategies were the most expensive.CONCLUSIONSSerum A. fumigatus-IgE is the optimal screening test for ABPA in asthma. It minimizes unnecessary testing while maintaining high diagnostic accuracy, making it a preferable approach in clinical practice.

2025-04-01·Ecotoxicology and Environmental Safety

Chloroxylenol and benzethonium chloride exposure alters spinal neuron development and behavior in developing zebrafish

Article

作者: Rerkamnuaychoke, Wuttiporn ; Svoboda, Kurt R ; Sreevidya, Virinchipuram S

Chloroxylenol (CHX) and benzethonium chloride (BEC) are replacement compounds being used after the ban (U.S. FDA) of triclosan and triclocarban in 2016 from personal care products. These two compounds are also recommended by the World Health Organization (WHO) as disinfectants against COVID-19. Toxicity data for both CHX and BEC are available, however, neurotoxicity studies for both compounds are still limited. Here, we determined the consequences of CHX and BEC exposure in a static exposure paradigm during embryogenesis on neurodevelopment using the zebrafish model (Danio rerio). CHX exposure (1-5 mg/L) dramatically impacted nervous system development without increasing mortality. The exposure altered embryonic motor output, primary motoneuron cell size, spinal interneuron cell size, primary motoneuron (PMN) axon pathfinding and secondary motoneuron (SMN) axon pathfinding. CHX exposure also altered slow muscle fiber development. Changes in neural activity as revealed by the induced changes in embryonic motor output (spontaneous coiling) may underlie the errors in PMN axon pathfinding as well as the changes in spinal interneuron morphology. Errors in SMN axon pathfinding resulting from CHX exposure were directly linked to errors in PMN axon pathfinding. Similar to CHX, BEC exposure (1-5 mg/L) altered embryonic motor output, spinal interneuron development, and slow muscle fiber development. In contrast to CHX, BEC exposure did not alter PMN or SMN axon pathfinding. Moreover, we found that BEC exposure (5 mg/L) from 5 to 96 hpf was lethal, resulting in almost 100 % mortality. Thus, these two triclosan replacement compounds exhibited markedly different modes of toxicity.

2025-03-01·The Journal of Allergy and Clinical Immunology: In Practice

Concurrent Blood Eosinophils and FeNO as Biological Therapy Indicators in Severe Asthma: Findings From the Precision Medicine Intervention in Severe Asthma Study

Article

作者: Lee, Ji-Hyang ; Kim, Hyunkyoung ; Park, ChanSun ; Song, Woo-Jung ; Kim, Mi-Yeong ; Cho, You Sook ; Kim, Joo-Hee ; Park, So Young ; Hur, Gyu Young ; Nam, Young-Hee ; Pham, Duong Duc ; Moon, Ji-Yong ; Park, Han Ki ; Kwon, Hyouk-Soo ; Park, So-Young ; Kim, Sujeong ; Kwon, Jae-Woo ; Lee, Taehoon ; Kim, Tae-Bum ; Kim, Byung Keun ; Yang, Min-Suk ; Cho, Young-Joo ; Adcock, Ian M ; Jung, Jae-Woo ; Chung, Kian Fan ; Bhavsar, Pankaj ; Kim, Sae-Hoon ; Lee, Byung-Jae ; Kim, Min-Hye

BACKGROUNDThe combination of pretreatment peripheral blood eosinophil count (BEC) and FeNO levels for optimizing the therapeutic response of T2-biologics in patients with severe eosinophilic asthma (SEA) remains unclear.OBJECTIVETo compare longitudinal clinical outcome changes across subgroups stratified by the combination of high and low levels of BEC and FeNO.METHODSOverall, 278 patients with SEA (anti-IL-5/IL-5Rα users: n = 82; and anti-IL-4Rα users: n = 196) were stratified based on pretreatment BEC and FeNO levels and observed for 6 to 12 months. Group differences in exacerbation rate, lung function, Asthma Control Test, BEC, FeNO, and clinical remission over time were compared.RESULTSApproximately 75% and 63% of patients presented with concurrent high BEC (≥300 cells/μL) and high FeNO (≥25 ppb) in the anti-IL-5/IL-5Rα and anti-IL-4Rα groups, respectively. Among anti-IL-5/IL-5Rα users, we observed no significant differences among BEC-FeNO groups regarding exacerbation rates or clinical remission. Patients with concurrent high BEC and FeNO levels demonstrated more pronounced reductions in both markers and greater FEV₁ and Asthma Control Test score improvements compared with those with high FeNO but low BEC. In the anti-IL-4Rα group, patients with low BEC and FeNO, and those with high BEC but low FeNO, exhibited a significantly lower likelihood of achieving clinical remission (odds ratio [95% CI]: 0.08 [0.00-0.46] and 0.11 [0.01-0.63], respectively) and a slower rate of FEV₁ improvement (all P for slope < .05) compared with those with concurrent high BEC and FeNO.CONCLUSIONConcurrently elevated BEC and FeNO levels ensure optimal therapeutic response in patients with SEA who are treated with T2 biologics.

100 项与阿雷地平相关的药物交易

登录后查看更多信息